Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant
Harry Pickering, Subha Sen, Janice Arakawa-Hoyt, Kenichi Ishiyama, Yumeng Sun, Rajesh Parmar, Richard S. Ahn, Gemalene Sunga, Megan Llamas, Alexander Hoffmann, Mario Deng, Suphamai Bunnapradist, Joanna M. Schaenman, David W. Gjertson, Maura Rossetti, Lewis L. Lanier, Elaine F. Reed, CMV Systems Immunobiology Group
Harry Pickering, Subha Sen, Janice Arakawa-Hoyt, Kenichi Ishiyama, Yumeng Sun, Rajesh Parmar, Richard S. Ahn, Gemalene Sunga, Megan Llamas, Alexander Hoffmann, Mario Deng, Suphamai Bunnapradist, Joanna M. Schaenman, David W. Gjertson, Maura Rossetti, Lewis L. Lanier, Elaine F. Reed, CMV Systems Immunobiology Group
View: Text | PDF
Research Article Immunology Transplantation

NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant

  • Text
  • PDF
Abstract

CMV causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired immunity that allows CMV reactivation is critical to guiding antiviral therapy and examining the effect of CMV on solid organ transplant outcomes. This study characterized longitudinal immune responses to CMV in 31 kidney transplant recipients with CMV viremia and matched, nonviremic recipients. Recipients were sampled 3 and 12 months after transplant, with additional samples 1 week and 1 month after viremia. PBMCs were stained for NK and T cell markers. PBMC transcriptomes were characterized by RNA-Seq. Plasma proteins were quantified by Luminex. CD8+ T cell transcriptomes were characterized by single-cell RNA-Seq. Before viremia, patients had high levels of IL-15 with concurrent expansion of immature CD56bright NK cells. After viremia, mature CD56dim NK cells and CD28–CD8+ T cells upregulating inhibitory and NK-associated receptors were expanded. Memory NK cells and NK-like CD28–CD8+ T cells were associated with control of viremia. These findings suggest that signatures of innate activation may be prognostic for CMV reactivation after transplant, while CD8+ T cell functionality is critical for effective control of CMV.

Authors

Harry Pickering, Subha Sen, Janice Arakawa-Hoyt, Kenichi Ishiyama, Yumeng Sun, Rajesh Parmar, Richard S. Ahn, Gemalene Sunga, Megan Llamas, Alexander Hoffmann, Mario Deng, Suphamai Bunnapradist, Joanna M. Schaenman, David W. Gjertson, Maura Rossetti, Lewis L. Lanier, Elaine F. Reed, CMV Systems Immunobiology Group

×

Figure 3

CD8+ T cells expressing inhibitory and NK-like receptors increase after CMV viremia.

Options: View larger image (or click on image) Download as PowerPoint
CD8+ T cells expressing inhibitory and NK-like receptors increase after ...
(A) CD8+ T cells as a percentage of lymphocytes for CMV PCR– patients 3 months (dark blue, n = 17) and 12 months after transplant (light blue, n = 24) and CMV PCR+ patients 3 months after transplant (purple, n = 14), 1 week after viremia (1WK PV, red, n = 19), 1 month after viremia (1M PV, orange, n = 9),and 12 months after transplant (yellow, n = 22). P values comparing CMV PCR– and CMV PCR+ at 3 and 12 months after transplant, determined by binomial logistic regression, and change over time after detection of viremia in CMV PCR+ patients, determined by linear regression, including patient ID as a random effect, are shown. (B) Ratio of CD28–/CD28+ CD8+ T cells as described above. (C) Mean percentage of CD28– (blue) and CD28+ (red) T cells expressing each marker. (D) Principal component analysis of individual marker expression values on CD28– (blue) and CD28+ (red) T cells. Ellipses represent 50% of patient variance per group, with increasing width of lines indicating increasing time after transplant for CMV PCR– patients and time after transplant and after detection of viremia for CMV PCR+ patients; full and dashed lines represent CD28– and CD28+ cells, respectively. Direction and strength of variance explained by each marker is indicated by annotated green arrows. Increasing evidence of transitional (CD28p_transitional), inhibitory (CD28n_inhibitory), and NK-like (CD28n_NK-like) phenotypes are highlighted.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts